Mersana Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Mersana Therapeutics has a total shareholder equity of $1.0M and total debt of $25.5M, which brings its debt-to-equity ratio to 2426.8%. Its total assets and total liabilities are $169.5M and $168.5M respectively.
Key information
2,426.8%
Debt to equity ratio
US$25.46m
Debt
| Interest coverage ratio | n/a |
| Cash | US$155.17m |
| Equity | US$1.05m |
| Total liabilities | US$168.48m |
| Total assets | US$169.53m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0M4's short term assets ($160.6M) exceed its short term liabilities ($68.3M).
Long Term Liabilities: 0M4's short term assets ($160.6M) exceed its long term liabilities ($100.2M).
Debt to Equity History and Analysis
Debt Level: 0M4 has more cash than its total debt.
Reducing Debt: 0M4's debt to equity ratio has increased from 5.2% to 2426.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0M4 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0M4 has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 15.2% each year.